Phase II data showed weight loss of up to approximately 20% at 52 weeks, with monthly dosing that could offer meaningful convenience advantages over weekly injections
The official FDA prescribing information for tirzepatide says to start at 2.5 mg regardless of what GLP-1 drug you were on before
Luna-Marco C, Iannantuoni F, Hermo-Argibay A, Devos D, Salazar JD, Vctor VM, et al
Semaglutide remains active in your body for several days after injection, and clinical evidence shows patients maintain weight loss even with minor interruptions
This underperformance reflects healthcares challenges: drug pricing pressures, slower innovation cycles outside oncology and rare diseases, and managed cares struggles with rising medical costs
Every minute at room temperature is unnecessary thermal exposure